Search

Your search keyword '"Domchek S.M."' showing total 245 results

Search Constraints

Start Over You searched for: Author "Domchek S.M." Remove constraint Author: "Domchek S.M."
245 results on '"Domchek S.M."'

Search Results

4. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

6. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.

8. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

9. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

10. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

11. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

12. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

13. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

14. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

15. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

16. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

17. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

18. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

19. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

20. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

21. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

22. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

23. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

24. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

25. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

26. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

27. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.

28. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

29. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

31. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2

32. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

33. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

34. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.

35. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer

36. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

37. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

38. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

39. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

40. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

41. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

43. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

44. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach

45. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

46. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

47. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

48. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

49. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk

50. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

Catalog

Books, media, physical & digital resources